By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an early blow to its new CEO as the Danish drugmaker battles to claw back lost ground in a fiercely competitive obesity drug market. Novo is going through a tumultuous period marked by a share price plunge and slowing sales growth, which have prompted a change of CEO and a board shake-up. It's also in a bidding war with U.S. rival Pfizer for bi ...